Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: ABBV-2222 Partially Corrects CFTR Function in CF Patients, Phase 2 Trials Show 31 Days of CF: Erin’s Story AzurRx Reaches Enrollment Goal in Trial of Therapy for CF Patients with EPI ABBV-2222 Partially Corrects CFTR Function in CF Patients, Phase 2 Trials Show May 29, 2019 07:00 am | Joana Carvalho Treatment with ABBV-2222, an investigational CFTR corrector formerly known as GLPG2222, was well-tolerated and partially corrected the function of the CFTR protein, both alone and in combination with Kalydeco (ivacaftor), in a group of patients with cystic fibrosis (CF), Phase 2 clinical trials show. Trial findings were published in the study, “CFTR activity is enhanced […] The post ABBV-2222 Partially Corrects CFTR Function in CF Patients, Phase 2 Trials Showappeared first on Cystic Fibrosis News Today. Read More 31 Days of CF: Erin’s Story May 28, 2019 12:59 pm | Luisa Palazola   View this post on Instagram   Day 6 of 31 Days of CF⁣ Topic: Best Friendships and CF ⁣ My name is Erin and, though, I don’t have CF, I’ve grown up knowing CF well. In January of 2008 I met my best friend, Danica. I remember thinking she was amazing right away (still […] The post 31 Days of CF: Erin’s Story appeared first on Cystic Fibrosis News Today. Read More AzurRx Reaches Enrollment Goal in Trial of Therapy for CF Patients with EPI May 28, 2019 07:00 am | Joana Carvalho AzurRx BioPharma has reached its patient enrollment goal in the ongoing Phase 2 trial testing the effectiveness of MS1819-SD, the company’s investigational therapy for the treatment of patients with exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF). MS1819-SD is a recombinant (artificial) form of an enzyme found in yeast (Yarrowia lipolytica) that breaks down […] The post AzurRx Reaches Enrollment Goal in Trial of Therapy for CF Patients with EPI appeared first on Cystic Fibrosis News Today. Read More   Recent News Agency Unveils RaDaR to Help Patient Groups Develop Rare Disease Registries Kalydeco’s Safety and Benefits Maintained Long-term in 2-to-5-year-olds with CF, Phase 3 Trial Shows 31 Days of CF: William’s Story The Work of ‘Project Fix Me’ Is Never Done Mutation in CFTR Gene Affects the Body’s Inner Clock, Mouse Study Suggests